To study the molecular pharmacology of low-voltage-activated calcium channels in biophysical detail, human medullary thyroid carcinoma (hMTC) cells were investigated using the singlechannel technique. These cells had been reported to express T-type whole-cell currents and a Ca v 3.2 (or ␣1H) channel subunit. We observed two types of single-channel activity that were easily distinguished based on single-channel conductance, voltage dependence of activation, time course of inactivation, rapid gating kinetics, and the response to the calcium agonist (S)-Bay K 8644. Type II channels had biophysical properties (activation, inactivation, conductance) typical for highvoltage-activated calcium channels. They were markedly stimulated by 1 M (S)-Bay K 8644, allowing to identify them as L-type channels. The channel termed type I is a low-voltageactivated, small-conductance (7.2 pS) channel that inactivates rapidly and is not modulated by (S)-Bay K 8644. Type
rapidly and is not modulated by (S)-Bay K 8644. Type I channels are therefore classified as T-type channels. They were strongly inhibited by 10 M mibefradil. Mibefradil block was caused by changes in two gating parameters: a pronounced reduction in fraction of active sweeps and a slight shortening of the open-state duration. Single recombinant low-voltage-activated T-type calcium channels were studied in comparison, using human embryonic kidney 293 cells overexpressing the pore-forming Ca v 3.2 subunit. Along all criteria examined (mechanisms of block, extent of block), recombinant Ca v 3.2 interact with mibefradil in the same way as their native counterparts expressed in hMTC cells. In conclusion, the pharmacologic phenotype of these native human T-type channels-as probed by mibefradil-is similar to recombinant human Ca v 3.2.
Nearly 2 decades ago, T-type calcium channels were discovered and described in neurons (Carbone and Lux, 1984) and heart cells (Bean, 1985; Nilius et al., 1985) . These lowvoltage-activated calcium channels open upon small depolarizations of the membrane potential, inactivate within milliseconds, and have a low single-channel conductance for Ba 2ϩ , compared with the high-voltage-activated calcium channels (Bean, 1985; Nilius et al., 1985; Droogmans and Nilius, 1989) . T-type calcium channels are found in a variety of tissues in which their role is only partially understood (Vassort and Alvarez, 1994) . T-type channels may differ considerably in their pharmacological properties depending on tissue or cell type (Huguenard, 1996) .
The molecular composition of the T-type calcium channel was elusive for many years, whereas in the case of highvoltage-activated channels, seven different genes encoding the pore-forming ␣1 subunit of the channel protein have been defined (␣1S and ␣1A-F) . Within the last 3 years, three new ␣1 subunits were cloned and named the ␣1G, ␣1H, and ␣1I subunits. This corresponds to Ca v 3.1, Ca v 3.2, and Ca v 3.3, respectively, according to the recent nomenclature (Ertel et al., 2000) . Extensive whole-cell studies of these recombinant subunits expressed in Xenopus laevis oocytes or human embryonic kidney cells reveal typical biophysical characteristics of native T-type calcium channels PerezReyes et al., 1998; Lee et al., 1999) , but at the single-channel level, only their conductance has been investigated. Another issue is whether any of the known auxiliary subunits associate with and modulate Ca v 3.X channels. Previous studies did not resolve this question (Dolphin et al., 1999; Lacinova et al., 1999; Klugbauer et al., 2000) .
In this study, we explored for the first time single-channel pharmacology of human native T-type and recombinant Ca v 3.2 channels. Our rationale was that single-molecule bio-physics and their modulation by drugs may give deeper insight into channel behavior and possibly its modulation by as-yet-unknown auxiliary subunits. For the native channels, we used a human cell line [human medullary thyroid carcinoma (hMTC)] because it expresses pure T-type calcium currents at the whole-cell level (Biagi et al., 1992) , and because a Ca v 3.2 (␣1H) channel was cloned from this source (Williams et al., 1999) . At least some auxiliary subunits (Hobom et al., 2000) are also expressed in hMTC cells. As a recombinant system, human Ca v 3.2 stably overexpressed in human embryonic kidney (HEK) 293 cells was used in comparison. The main pharmacological tool employed was mibefradil, a known selective nondihydropyridine blocker of native (Mishra and Hermsmeyer, 1994 ; see also Bezprozvanny and Tsien, 1995) and recombinant T-type channels. Mibefradil was also of interest because it differentiates between coexpressed auxiliary ␤-subunits when interacting with another voltage-dependent calcium channel, Ca v 1.2 (Welling et al., 1995) .
To our initial surprise, a high-voltage-activated calcium channel is also observed in hMTC cells at the singlechannel level. We provide evidence that those two channels can easily be discriminated from each other and represent T-and L-type channels, respectively. The singlechannel pharmacology of the T-type is extensively analyzed and compared with its recombinant counterpart. We demonstrate that mibefradil blocks both native T-type and recombinant Ca v 3.2 channels by two mechanisms (i.e., a reduction of the fraction of active sweeps and a slight reduction of open times).
Materials and Methods
Cell Culture. hMTCcells were grown in RPMI 1640 medium (Biochrom KG, Berlin, Germany) supplemented with 10% fetal bovine serum (Sigma, Deisenhofen, Germany), penicillin (50 units/ml), and streptomycin (50 g/ml). Cells were plated onto polystyrene dishes. HEK 293 cells have been stable transfected with the human Ca v 3.2 without auxiliary subunits as described previously Lee et al., 1999) . Cells were grown in Dulbecco's modified Eagle's medium (Biochrom KG) supplemented with fetal bovine serum (Sigma) and G418 (1 mg/ml; Invitrogen, Karlsruhe, Germany). Cells were grown onto polystyrene dishes coated with 0.1% gelatin, which also served as recording chambers. For electrophysiological experiments, cells were used on the second day (hMTC) or on the first to third day (HEK 293) after plating.
Electrophysiology. Single calcium channels were recorded in the cell-attached configuration of the patch-clamp technique. Experiments were performed in an external solution containing 120 mM K-glutamate, 25 mM KCl, 2 mM MgCl 2 , 10 mM HEPES, 2 mM EGTA, 1 mM CaCl 2 , 1 mM Na-ATP, and 10 mM dextrose, pH 7.4. Pipettes (borosilicate glass, 6-7 M⍀) were filled with 110 mM BaCl 2 and 10 mM HEPES, pH 7.4. Ba 2ϩ currents were elicited by depolarizing test pulses delivered at 0.5 Hz, recorded at 10 kHz and filtered at 2 kHz (Ϫ3 dB, four-pole Bessel) using an Axopatch 1D or Axopatch 200 A (Axon Instruments, Union City, CA). The pClamp software (versions 5.5 and 6.0, Axon Instruments) was used for data acquisition and analysis. Drugs were added to the bath as a 20-l bolus of an appropriate stock solution, assuming a bath volume of 2 ml. At the end of the experiments, the actual bath volume was measured, and the exact drug concentration was calculated. All experiments were carried out at room temperature (21-23°C).
Drugs. Mibefradil was a gift of Hoffmann-La Roche (Basel, Switzerland). It was prepared as a 10 mM stock solution in H 2 O, which was freshly diluted with bath solution to 0.1 mM on each experimental day. (S)-Bay K 8644 (Sigma/RBI, Natick, MA) and nitrendipine (Sigma) were dissolved and stored light-protected in absolute ethanol as 10 mM stock solutions and diluted to 0.1 mM for daily use. The final ethanol concentration in the bath was Յ 0.11%. Data Analysis. Linear leak and capacity currents were digitally subtracted using the average currents of nonactive sweeps. Openings and closures were identified using the half-height criterion (pClamp 6.0). For analysis of data obtained with Ca v 3.2 we also used custommade software (Patch 0.2) that employs the same idealization algorithm but allows for improved leak subtraction and data-editing features. Data were further analyzed by histogram analysis (see below). Closed time analysis was restricted to patches where only one channel was present. NP o (the product of the number of channels in the patch times their individual open probability) was calculated as the ratio between the total open time and the total recording time at the test potential. P o (the single channel open probability) was calculated as the ratio of the total open time and the total time recorded at the test potential, divided by the number of channels in the patch (N) where necessary and possible. f active (the fraction of sweeps containing at least one opening) was corrected by the squareroot method: 1 Ϫ f active, corrected ϭ (1 Ϫ f active, uncorrected ) 1/N for multichannel patches in hMTC cells. The number of channels in the patch was estimated here by dividing the maximum current observed with stacked openings through the unitary amplitude. P o, active (the open probability within active sweeps) was computed as the ratio P o /f active . The voltage-dependence of f active and P o was analyzed using the Boltzmann function: Y ϭ Y max /{1 ϩ e (V0.5 Ϫ V/k) }, where V 0.5 is the voltage of half-maximal (in)activation and k is the slope factor. Single-channel amplitudes (i) were determined by direct measurements of fully resolved openings or as the maximum of Gaussian fits to all-point amplitude histograms of "semi"-idealized openings [semi-idealized traces: raw data during openings but idealized (zeroed) baseline]. I peak was determined as the maximum of ensemble average currents. The time course of inactivation (i) was analyzed by fitting nonlinear approximation the ensemble average current I to the equation I (t) ϭ I max. ϫ (1 Ϫ e Ϫt/a ) 2 ϫ e Ϫt/i (Droogmans and Nilius, 1989; Huguenard, 1996) 
Results
In cell-attached recordings, we obtained two visually distinct types of single-channel activity, which we initially termed "type I" and "type II" behavior. Representative examples from two experiments are compiled in Fig. 1 . At first glance, types I and II differ in at least four different aspects. For type I, it activates at lower voltages, it has a lower single-channel amplitude at any given test potential, openings occur in well-separated bursts at any given test potential, and the ensemble average current inactivates rapidly. For type II, openings are more evenly distributed, and average currents do not visibly undergo time-dependent inactivation. We will systematically compare these properties one by the other in the following.
The voltage-dependences of activation and inactivation were analyzed by plotting f active (measured from at least 60 test pulses) against the voltage of the test potential or holding potential, respectively. The pooled data are shown in Fig.  2 , A and B. Individual type I channels activate half-maximally at Ϫ17.7 Ϯ 2.9 mV, with a slope factor of 4.3 Ϯ 1.0 mV (n ϭ 4). Half-maximal inactivation occurs at Ϫ51.1 Ϯ 3.5 mV with a slope of Ϫ7.6 Ϯ 1.4 mV (n ϭ 7). A small window current is suggested by the overlap of these curves between Ϫ40 mV and Ϫ20 mV . For type II, inactivation lies in the same order of magnitude (V 0.5 , Ϫ48.8 Ϯ 2.3 mV; slope, Ϫ7.9 Ϯ 0.7 mV; n ϭ 3), but activation occurs at much more positive potentials (V 0.5 , Ϫ8.0 Ϯ 0.9 mV; slope, 7.5 Ϯ 2.0 mV; n ϭ 4, p Ͻ 0.05). Maximum f active was always Ϸ 50%. When analyzing P o in a similar manner (Fig. 2, C and D) , the maximum values of activation curves were more variable, and saturation was not clearly evident at the most positive test potentials where openings still could be resolved (Cachelin et al., 1983 ). Yet, potentials of half-maximum activation and inactivation gave results consistent with f active for both type I (activation: V 0.5 , Ϫ13.9 Ϯ 4.7 mV; slope, 4.9 Ϯ 0.6 mV; n ϭ 6; inactivation: V 0.5 , Ϫ66.3 Ϯ 4.6 mV; slope, Ϫ12.5 Ϯ 3.1 mV; n ϭ 5) and type II (activation: V 0.5 , 17.9 Ϯ 5.2 mV; slope, 7.2 Ϯ 0.7 mV; n ϭ 5; inactivation: V 0.5 , Ϫ45.8 Ϯ 4.9 mV; slope, Ϫ6.9 Ϯ 2.5 mV; n ϭ 4) channels, respectively.
The difference between type I and type II regarding singlechannel conductance is illustrated in Fig. 3 . Type I channels (closed symbols) have a lower single-channel current amplitude at any given test potential, and the slope conductance, calculated individually by linear regression, is significantly lower, too (type I, 7.2 Ϯ 0.6 pS, n ϭ 10; type II, 14 Ϯ 1 pS, n ϭ 10).
The most prominent difference regarding rapid gating was the bursting pattern of openings, which was evident over the whole voltage range in the case of type I channels. Therefore, we analyzed the closed-time distribution of type I and II channels at a test potential of 0 mV, where single-channel events could still be resolved for type I channels, and channel activity was already substantial for type II (see Fig. 1 ). As seen in Fig. 4 , both channel types clearly reveal two components in their closed-time histograms. The slow component had a comparable time constant, 2 , that amounted to 22.1 Ϯ 4.2 ms (n ϭ 4) for type I and 22.0 Ϯ 2.8 ms (n ϭ 5) for type II channels. The 1 extrapolated from maximum likelihood fits, Fig. 1 , we were able to analyze the voltage-dependence of the inactivation time course (i) by nonlinear approximation (see Materials and Methods). In the case of type I, inactivation was fast and accelerated by more positive test voltages: the i values were 62 Ϯ 23 ms, 31 Ϯ 11 ms, and 31 Ϯ 2 ms (n ϭ 3-5) at voltages of Ϫ10 mV, 0 mV, and ϩ10 mV, respectively. In contrast, i values increased with voltage in the case of type II: 62 Ϯ 3 ms at 0 mV, 77 Ϯ 13 ms at ϩ10 mV, 349 Ϯ 126 ms at ϩ20 mV, and 458 Ϯ 120 ms at ϩ30 mV (n ϭ 3-4). Further examples illustrating the different inactivation behavior can be seen in Figs. 6 and 7.
To exclude the possibility that our analysis of type I versus type II channels is biased by a selection artifact, we checked our identification by plotting two of the proposed distinctive biophysical features against each other (Fig. 5) , single-channel conductance and mean closed time (at 0 mV, from onechannel patches only). It can be seen that there is no single case of overlap between those two parameters, which are not inherently dependent on each other.
In a second series of experiments, we tested our hypothesis that type I and II channels represent different entities by Comparison between channels classified visually as type I (, n ϭ 6) and type II (Ⅺ, n ϭ 7) using two independent biophysical criteria: conductance (abscissa, see Fig. 3 ) and mean closed time (ordinate, see Table 1 ). Only one-channel patches were included. There is no overlap between the values covered by each criterion, and there is no case of ambiguity, as indicated by the two empty quadrants. Table 1 ), the drug enlarged single-channel amplitude (from 0.89 Ϯ 0.04 pA to 1.13 Ϯ 0.09 pA). Conductance was raised to 23.1 Ϯ 1.0 pS (n ϭ 9). Downloaded from using a pharmacological approach. Channels were classified as type I or II during the early course of the experiments according to the criteria mentioned above. Type I channels were then step-depolarized to Ϫ10 mV (Fig. 6 ) and type II channels to ϩ10 mV (Fig. 7) , offering optimal activity and recording conditions for each case. After a control period, channels were then exposed to either solvent, the L-type calcium-channel agonist (S)-Bay K 8644, or the T-type channel blocker mibefradil. Under control conditions, type II but not type I channels underwent some decline in activity ("run Fig. 8 . Open probability P o (averaged over 2-min recording periods) of type I channels versus time. Channels were depolarized to Ϫ10 mV and exposed after 6 min to solvent (top, n ϭ 8), mibefradil (middle, 10.0 Ϯ 0.1 M, n ϭ 13), or (S)-Bay K 8644 (bottom, 1.02 Ϯ 0.01 M, n ϭ 10). Fig. 9 . Open probability P o (averaged over 2-min recording periods) of type II channels versus time. Channels were depolarized to ϩ10 mV and exposed after 6 min to solvent (top, n ϭ 10), mibefradil (middle, 9.7 Ϯ 0.3 M, n ϭ 7), or (S)-Bay K 8644 (bottom, 1.01 Ϯ 0.01 M, n ϭ 9). Table 1 ). (S)-Bay K 8644 (1.02 Ϯ 0.01 M) had no effect on type I channels. Mibefradil (9.7 Ϯ 0.3 M) inhibited I peak of type II channels by 50% of predrug values. This effect was caused by a corresponding change in f active , whereas open times remained unaffected.
Pharmacology of Single
In contrast, mibefradil effects on type I channel ensemble average current are composed of two components. First, the fraction of active sweeps again is strongly depressed; in addition, open probability within active sweeps is also reduced to a significant extent, because of a corresponding change in mean open times (Table 1) . To address these two components of inhibition in a more quantitative manner, further analysis was performed. The slow gating kinetics of channel "availability" (i.e., transitions between active and nonactive, or blank sweeps), can be analyzed by sweep histogram analysis (Herzig et al., 1993) . Blank-sweep histograms were constructed by plotting the cumulative probability density function of series of continuously nonactive sweeps. In the seven experiments with one type I channel in the patch, blanksweep histograms were well characterized by a single exponential component before mibefradil was applied. The time constant of the underlying nonactive state amounted to ϭ 2.68 Ϯ 0.26 s. When data from the seven experiments were pooled (1611 sweeps in total), a similar value of 2.66 s was obtained (Fig. 10 A) . After application of 10 M mibefradil, a second, slow component became obvious, 2 ϭ 22.1 Ϯ 4.8 s (n ϭ 7) together with the faster component, the 1 (2.84 Ϯ 0.36 s, n ϭ 7), which matched the value obtained under control conditions (see above). Again, results from the pooled analysis (Fig. 10B) were similar ( 1 ϭ 2.82 s; 2 ϭ 16.7 s). This indicates that fraction of active sweeps is reduced by mibefradil because the channel occasionally adopts a long-lived nonactive, blank state. The lifetime of this state can be taken as a measure of the rate of dissociation of the drug (1/ Ϸ 0.05/s).
Open-time histograms confirm the significant effect of mibefradil seen on mean open time (Table 1) . As exemplified in Fig. 11 Table 1 ), together with a lack of effect on closed times, is also compatible with the idea that the drug leads to a rapid, short-lived block of channels on the order of Ͻ 1 ms.
HEK 293 cells expressing Ca v 3.2 channels were first examined using a pulse protocol in which channels were fully available (holding at Ϫ90 mV, test pulses to Ϫ20 mV). This gave rise to large, rapidly activating and inactivating currents (Fig. 12 A) , but clear-cut unitary events were discernible only during the second half of the test pulse. Every single trace-with some variance regarding peak amplitude-resembled the current wave form obtained by averaging the whole ensemble (Fig. 12A, bottom trace) . Mibefradil (10 M; 8.9 Ϯ 0.6 M, n ϭ 5) considerably reduced channel activity regarding peak currents. Open probability was markedly reduced, such that nonstacked unitary events were now also observed early in the pulse (Fig. 12 B) . The ensemble averages still revealed the typical features of a rapidly activating and inactivating channel. Mibefradil lowered the maximum ensemble average current (I peak ) significantly from Ϫ567 Ϯ 122 to Ϫ189 Ϯ 40 fA. Hence, overexpression had led to a high channel density in every patch examined, and we made no further attempts to characterize single-channel gating (or mibefradil effects) under the conditions of this voltage protocol.
Instead, depolarizing steps from Ϫ50 to Ϫ20 mV were Effects of solvent, mibefradil (type I, 10.0 Ϯ 0.1 M; type II, 9.7 Ϯ 0.3 M), and (S)-Bay K 8644 (type I, 1.02 Ϯ 0.01 M; type II, 1.01 Ϯ 0.01 M) on single-channel parameters of type I and II channels in hMTC cells. Data were collected from 0 to 6 min of recording for the first period and from 7 min to the end of experiments for the second period in the case of (S)-Bay K 8644 and solvent. For mibefradil experiments, the first 4 min after application were excluded to allow analysis of the steady-state drug effect (see Figs. 8 and 9). I peak was measured from ensemble average currents, f active represents the fraction of active sweeps, open and closed times were averaged from all detected events, and P o, active was calculated as the open probability within active sweeps. chosen to induce voltage-dependent steady-state inactivation, which dramatically minimized the number of simultaneously available channels, compared with a holding potential of Ϫ90 mV. This made it possible to detect and analyze separate unitary events in both the absence and the presence of mibefradil (Fig. 13) . Stacked openings of twice the unitary amplitude were rarely observed. Channel activity remained stable over time in cells not exposed to drug (Fig. 14, top) . In the presence of 10 M mibefradil (9.3 Ϯ 0.5 M, n ϭ 8), the peak inward current obtained from ensemble averages was found to decrease significantly from Ϫ46 Ϯ 5 fA to Ϫ24 Ϯ 4 fA. In view of the (sub)micromolar IC 50 values reported for mibefradil in whole-cell studies on Ca v 3.2 Williams et al., 1999) we tested a lower concentration of 3.3 Ϯ 0.1 M ( Table 2 ). This concentration caused qualitatively similar but smaller effects (I peak , from Ϫ93 Ϯ 24 fA to Ϫ69 Ϯ 24 fA; NP o , from 11 Ϯ 3.2% to 7.0 Ϯ 2.9%, p Ͻ 0.05, n ϭ 6). Selectivity of the action of 10 M mibefradil on these channels was further examined by applying the same concentration of nitrendipine (10.3 Ϯ 0.2 M, n ϭ 6), a selective blocker of single L-type calcium channels (Kawashima and Ochi, 1988) . As expected, Ca v 3.2 channels were not blocked significantly by this compound ( Fig. 14 ; Table 2 ). The mechanism of inhibition by 10 M mibefradil was now studied in more detail at the single-channel level. As illustrated in Fig. 13 , the number of sweeps containing channel activity f active was significantly lowered by 10 M mibefradil from 67 Ϯ 5 to 40 Ϯ 5%. It should be noted that these numbers only give a lower-limit estimate for the effect on true f active of each single channel involved, because we are unable to determine the total number of channels participating in channel activity. . This problem, however, should be less severe during the second half of the test pulses, where openings are very rare and fusion rather unlikely. Indeed, when studying the second half of test pulses, the mibefradil effect on mean open times was well preserved (from 0.76 Ϯ 0.10 ms to 0.64 Ϯ 0.09 ms, p ϭ 0.06, n ϭ 8).
To examine the possibility of an additional, very rapid block in the range of microseconds, we constructed all-point histograms (Fig. 16 ) from raw data after semi-idealization of the data sets (see Materials and Methods). Single-channel amplitude, as determined by Gaussian fits to the nontruncated portion of histograms, remained unaffected by 10 M mibefradil both in native (Fig. 16A , control: Ϫ0.40 Ϯ 0.02 pA; B, after mibefradil: Ϫ0.41 Ϯ 0.03 pA, n ϭ 13, n.s.) and in recombinant channels (Fig. 16C , control: Ϫ0.41 Ϯ 0.01 pA; D, after mibefradil: Ϫ0.42 Ϯ 0.02 pA, n ϭ 8, n.s.).
In summary, mibefradil exerted a dual mechanism of block, affecting f active and open times, in Ca v 3.2 channels.
The "pharmacological phenotype" of the recombinant channels-as far as it can be resolved by analysis of multichannel patches-is therefore indistinguishable from its native counterpart expressed in hMTC cells.
Discussion
The main results of this study are that two types of single calcium channels are present in a human C-cell tumor line (hMTC), that these channels can easily be distinguished by their biophysical properties, that these channels fulfill the necessary criteria to be classified as T-type or L-type channels respectively, that mibefradil blocks T-type channels by reducing fraction of active sweeps and open times, but not single-channel amplitude, and that mibefradil effects are identical when studied in recombinant Ca v 3.2 channels.
The large-conductance channel (type II) inactivates slowly (Fig. 1B) and activates at high voltages (Fig. 2B) . The voltage-dependence of activation and inactivation, measured under continuous pulsing rather than with conventional twopulse protocols, is reminiscent of native cardiac human L-type channels (Handrock et al., 1998; Kreuzberg et al., 2000) . The single-channel conductance under basal conditions (Ϸ14 pS) does not discriminate between various members of the high-voltage-activated channel family, but conductance can be more accurately determined using the wellresolved openings in the presence of the calcium-channel agonist (S)-Bay K 8644 (Fig. 7) . The value obtained here (23 pS) is in line with reports on L-type channels (McDonald et al., 1994) under similar conditions, and such an increase found with calcium agonists has been noted previously (Lacerda and Brown, 1989; Handrock et al., 1998; Kreuzberg et , 2000) . Importantly, a stimulatory response to calcium agonists per se (Figs. 7 and 9 ) is a hallmark feature of L-type (Hess et al., 1984) but not other types of voltage-activated calcium channels. In characteristic distinction (Nilius et al., 1985; McDonald et al., 1994) to the low-voltage-activated channel we observed, type II channels exhibited time-dependent loss of activity [i.e., "run down" (Figures 8 and 9) ]. On the basis of our results, the molecular entity (␣1C, ␣1D, ␣1F, or ␣1S, corresponding to Ca v 1.2, Ca v 1.3, Ca v 1.4, and Ca v 1.1, respectively) that represents the pore-forming unit cannot be determined, although the source of cells (endocrine) favors the first two possibilities (Ertel et al., 2000) . Furthermore, it remains unclear why previous investigators did not detect an L-type current at the whole-cell level (Biagi et al., 1992 ; but see Mehrke et al., 1994) , despite the observation that hormone secretion in primary human MTC-cells is stimulated and inhibited by dihydropyridine agonist and antagonist, respectively (Raue et al., 1989) . We observed marked periodic changes in the occurrence of type II, but not type I, channels over the course of the project, which were independent of passage number or batch of cells (not shown). The inhibition of the L-type channel by mibefradil, known from other systems (e.g., Bezprozvanny and Tsien, 1995; Welling et al., 1995) but seen here for the first time with single channels, merits further analysis once the molecular channel entity is identified (see above).
The type I behavior reported here fulfills all tested criteria of a T-type, Ca v 3.X channel, namely activation in the lowvoltage range (Figs. 1-3 ) and low conductance of 7 to 8 pS ( Fig. 3 ) with isotonic Ba 2ϩ (Nilius et al., 1985 ; note that the lower value of 5.3 pA reported by Cribbs et al., 1998 , was obtained at much more negative potentials), fast inactivation (Fig. 1B) , and sensitivity toward mibefradil . Deactivation was not studied here, as the long pulses
Fig. 14. Open probability NP o (averaged over 2-min recording periods) of recombinant Ca v 3.2 channels versus time. Channels were held at Ϫ50 mV and depolarized to Ϫ20 mV. They were exposed either to no drug (top, n ϭ 6), or to mibefradil after 6 min (middle, 9.3 Ϯ 0.5 M, n ϭ 8), or to nitrendipine after 4 min (bottom, 10.3 Ϯ 0.2 M, n ϭ 5). molpharm.aspetjournals.org used (150 ms) gave rise to only a few tail openings, which were not further analyzed. The clear-cut two components of the closed-time distribution, with an ultrashort first component, have also been described previously as characteristic for native T-type channels (Droogmans and Nilius, 1989; Chen and Hess, 1990) . Based on cloning work (Williams et al., 1999) , we suggest that type I channels described here represents the human ␣1H (or Ca v 3.2) isoform in its native environment. Notably, the effect of mibefradil on this channel comprises two components: a major reduction of fraction of active sweeps due to a long-lived interaction and a minor component reflected by a shortening of open times.
This study is the first to examine the single-channel mechanism of mibefradil to block a recombinant human low-voltage-activated calcium channel, Ca v 3.2. Unlike the situation with native channels in hMTC cells, the high level of overexpression of channels in HEK 293 cells made it inevitable to perform multichannel recordings. Yet, partial depolarization of the holding potential enabled us to perform a focused analysis of single-channel gating before and after drug application.
Interestingly, mibefradil-induced inhibition again seemed to consist of two components. Blockade that leads to a reduced fraction of active sweeps is indicative for a long-lived drug-channel interaction outlasting the duration of the test pulse (here, 150 ms). This type of effect is known for classical calcium-channel blockade in Ca v 1.X, as with gallopamil (Pelzer et al., 1984) or nitrendipine (Hess et al., 1984) , and can be analyzed kinetically (Kawashima and Ochi, 1988) . In our case, only single-channel patches from hMTC cells allowed such an analysis, revealing a dissociation rate on the order of 0.05/s in the presence of mibefradil (see above). In addition, and in clear kinetic distinction, open times were shortened, which points to another type of interaction on the order of milliseconds and implies open-channel blockade. Of note, Gomora et al. (2000) measured a mibefradil effect of similar size on whole-cell deactivation kinetics, although these authors did not highlight this result. Open-channel block is known for other calcium-channel blockers, at least at high concentrations (Pelzer et al., 1984; Kawashima and Ochi, 1988) . Very rapid block in the range of microseconds-which would manifest as a reduced apparent single-channel current amplitude at our recording bandwidth (Hille, 1992 )-was absent both in native and recombinant channels (Fig. 16 ).
Such type of block is more common for small pore-blocking particles but has been observed with larger organic molecules (Gingrich et al., 1993) .
Largely different time scales of channel block-as seen here-are commonly assigned to different types of channel blockers, each with particular dwell times of binding (Hille, 1992) . Because we observed different kinetics within one drug, we may speculate about factors affecting the mechanism of block. The chemical structure of mibefradil contains a benzimidazolyl group and a tertiary amino group. Thus, resulting charge heterogeneity may cause differences in channel interaction (Kass and Arena, 1989; Abernethy, 1997) .
We were quite concerned about the high concentrations of mibefradil necessary for an approximately half-maximum block. Given the (sub)micromolar inhibition constant reported for Ca v 3.2 under whole-cell conditions Martin et al., 2000) we provide several lines of evidence that the Ϸ 10-fold lower affinity of block is still indicative of a specific drug-channel interaction: a dihydropyridine agonist [(S)-Bay K 8644] and an antagonist (nitrendipine 10 M) have no effect in our systems, and mibefradil at a 3-fold lower concentration exerted only minor effects, indicating that we are working in the appropriate range of concentrations. These findings indicate that the low affinity of mibefradil is caused by the particular experimental conditions necessary for single-channel recording. We cannot decide at present whether accessibility limitations imposed by the cell-attached configuration, the high concentration of divalent cations, or both are responsible. The latter mechanism is supported by whole-cell studies (Martin et al., 2000) . The former idea is less likely, given the ease of cellular accumulation of mibefradil (Wu et al., 2000) , but can be rigorously tested using the inside-out or outside-out excised patch conformation.
HEK 293 cells used in this work overexpress pore-forming Ca v 3.2 channel subunits . The existence of endogenous auxiliary subunits cannot be firmly excluded, because native HEK 293 can express endogenous small lowvoltage-activated currents under some conditions (Berjukow et al., 1996) . However, we consider it unlikely that those subunits are quantitatively sufficient to modulate transfected Ca v 3.2. Therefore, we conclude that the natural set of accessory subunits possibly coexpressed (in stoichiometric amounts) with native T-type calcium channels in hMTC cells plays no detectable role with regard to single-channel activity under baseline conditions or to mibefradil block. However, a thorough biophysical analysis of recombinant channels under baseline conditions was hampered by technical limitations of the expression system: holding potentials negative to Ϫ50 mV inevitably led to multiple overlapping channel openings (Fig. 12) , and test potentials positive to Ϫ20 mV could not be analyzed because of inadequate signal-to-noise ratios and insufficient seal stability. This article presents the first description of mibefradil blockade of native and recombinant Ca v 3.X channels at the single-channel level. We found that mibefradil caused a profound blockade of T-type-and Ca v 3.2-mediated calcium channel currents, which consisted of two kinetically distinct components. Our results show that recombinant (Ca v 3.2) and native T-type calcium channels share a common pharmacological phenotype as probed by mibefradil. Hence, we conclude that hMTC cells express both T-type and L-type calcium channels, hMTC cells and HEK 293 cells overexpressing the Ca v 3.2 subunit are useful tools for single-channel studies on low-voltage-activated calcium channels, offering distinct advantages and limitations, and mibefradil block in both systems reveals two kinetically distinct components at the single-channel level, suggesting two distinct mechanisms of block. 
